• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EGFR野生型和突变型非小细胞肺癌患者早期和晚期脑转移的影像学特征及生存情况

Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer.

作者信息

Yuan Ren, Yamada Andrew, Weber Britta, Ho Cheryl

机构信息

Department of Diagnostic Imaging, BC Cancer Agency, Vancouver, BC, Canada.

Department of Medical Oncology, BC Cancer Agency, 600 W 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.

出版信息

J Neurooncol. 2016 May;127(3):525-33. doi: 10.1007/s11060-016-2057-5. Epub 2016 Jan 16.

DOI:10.1007/s11060-016-2057-5
PMID:26780337
Abstract

Brain metastasis (BM) in NSCLC is a negative prognostic indicator. In the era of EGFR mutations we evaluated the difference between early (≤6 months from diagnosis) versus late BM (>6 months), in EGFR wild type (WT) and mutant (MT) NSCLC patients with respect to radiographic patterns and overall survival (OS). A retrospective study was conducted of referred patients with non-squamous NSCLC with known EGFR mutation status treated for BM from Mar 2010-Dec 2012. Radiographic patterns, treatment and survival were collected. 430 patients were identified: 327 WT (207 early vs. 120 late) and 103 MT (65 early vs. 38 late). Early and late BM radiographic patterns were similar in EGFR WT patients. In EGFR MT there was a trend towards multiple lesions in the late compared to early BM group. OS from initial diagnosis early BM: WT 7.1 months versus MT 19.9 months (p < 0.001). OS from initial diagnosis late BM: WT 24.9 months versus MT 25.6 months (p = 0.51). In multivariate analysis chemotherapy, single lesion and late BM were associated with better survival in WT patients whereas age, and systemic treatment but not BM timing or single lesion were predictive of better outcomes in MT patients. In early BM, EGFR MT have an OS comparable to late BM. In contrast, early BM EGFR WT have a significantly reduced survival compared to late BM. The positive outcome in EGFR MT may be secondary to systemic control and EGFR TKI penetrance across the blood brain barrier.

摘要

非小细胞肺癌(NSCLC)脑转移(BM)是一个不良预后指标。在表皮生长因子受体(EGFR)突变时代,我们评估了EGFR野生型(WT)和突变型(MT)NSCLC患者中早期(诊断后≤6个月)与晚期BM(>6个月)在影像学特征和总生存期(OS)方面的差异。对2010年3月至2012年12月期间因BM接受治疗且已知EGFR突变状态的非鳞状NSCLC转诊患者进行了一项回顾性研究。收集了影像学特征、治疗情况和生存数据。共确定了430例患者:327例WT(207例早期与120例晚期)和103例MT(65例早期与38例晚期)。EGFR WT患者的早期和晚期BM影像学特征相似。在EGFR MT中,与早期BM组相比,晚期有多发灶的趋势。从初始诊断开始的早期BM的OS:WT为7.1个月,而MT为19.9个月(p<0.001)。从初始诊断开始的晚期BM的OS:WT为24.9个月,而MT为25.6个月(p=0.51)。多因素分析显示,化疗、单发病灶和晚期BM与WT患者更好的生存相关,而年龄和全身治疗而非BM时间或单发病灶可预测MT患者的更好结局。在早期BM中,EGFR MT的OS与晚期BM相当。相比之下,早期BM的EGFR WT与晚期BM相比生存显著降低。EGFR MT的良好结局可能继发于全身控制以及EGFR酪氨酸激酶抑制剂(TKI)穿过血脑屏障的渗透率。

相似文献

1
Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer.EGFR野生型和突变型非小细胞肺癌患者早期和晚期脑转移的影像学特征及生存情况
J Neurooncol. 2016 May;127(3):525-33. doi: 10.1007/s11060-016-2057-5. Epub 2016 Jan 16.
2
Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.立体定向放射治疗后,生存情况而非脑转移反应与肺癌突变状态相关。
J Neurooncol. 2016 Feb;126(3):483-91. doi: 10.1007/s11060-015-1986-8. Epub 2015 Oct 31.
3
Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.脑和肺部病变手术切除后序贯 EGFR-TKIs 治疗,可使 EGFR 突变型非小细胞肺癌伴孤立性脑转移患者获得长期生存。
World J Surg Oncol. 2017 Oct 16;15(1):184. doi: 10.1186/s12957-017-1252-y.
4
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.非小细胞肺癌患者的表皮生长因子受体突变与脑转移模式
Korean J Intern Med. 2018 Jan;33(1):168-175. doi: 10.3904/kjim.2015.158. Epub 2016 Apr 20.
5
Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.根据 KRAS 突变状态对晚期非鳞状 EGFR 野生型非小细胞肺癌患者进行铂类化疗的临床结果。
Clin Lung Cancer. 2014 Jan;15(1):86-92. doi: 10.1016/j.cllc.2013.08.002. Epub 2013 Oct 17.
6
EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)联合全脑放疗(WBRT)并未为非小细胞肺癌(NSCLC)伴表皮生长因子受体(EGFR)突变和脑转移患者带来生存获益,除 TKIs 单药治疗外。
J Thorac Oncol. 2016 Oct;11(10):1718-28. doi: 10.1016/j.jtho.2016.05.013. Epub 2016 May 26.
7
Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.表皮生长因子基因外显子 19 或 21 突变的非小细胞肺癌患者伴脑转移的预后分析。
BMC Cancer. 2020 Sep 3;20(1):837. doi: 10.1186/s12885-020-07249-7.
8
Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.表皮生长因子受体突变和间变性淋巴瘤激酶重排对非小细胞肺癌脑转移患者结局的影响。
Neuro Oncol. 2020 Feb 20;22(2):267-277. doi: 10.1093/neuonc/noz155.
9
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).在法国前瞻性队列研究(ERMETIC 项目-第 2 部分)中,对接受厄洛替尼治疗的晚期非小细胞肺癌患者进行系统 EGFR 和 KRAS 突变评估对无进展生存期和总生存期的影响。
J Thorac Oncol. 2012 Oct;7(10):1490-502. doi: 10.1097/JTO.0b013e318265b2b5.
10
Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.表皮生长因子受体突变的非小细胞肺癌发生脑转移患者延迟放疗的影响
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):673-9. doi: 10.1016/j.ijrobp.2016.01.037. Epub 2016 Feb 2.

引用本文的文献

1
Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.美国有或无脑转移的晚期非小细胞肺癌患者的临床基因组因素和治疗模式。
Oncologist. 2023 Nov 2;28(11):e1075-e1091. doi: 10.1093/oncolo/oyad170.
2
Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer.非小细胞肺癌中的表皮生长因子受体突变与脑转移
Front Oncol. 2022 Nov 15;12:912505. doi: 10.3389/fonc.2022.912505. eCollection 2022.
3
Individualized Nomogram for Predicting Survival in Patients with Brain Metastases After Stereotactic Radiosurgery Utilizing Driver Gene Mutations and Volumetric Surrogates.

本文引用的文献

1
Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort.晚期非小细胞肺癌的转诊模式:对当代基于人群队列中治疗和生存的影响。
Lung Cancer. 2014 Dec;86(3):344-9. doi: 10.1016/j.lungcan.2014.09.016. Epub 2014 Oct 2.
2
Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival.肺腺癌中的脑转移:EGFR 突变状态对发病率和生存的影响。
Radiol Oncol. 2014 Apr 25;48(2):173-83. doi: 10.2478/raon-2014-0016. eCollection 2014 Jun.
3
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
利用驱动基因突变和体积替代指标预测立体定向放射治疗后脑转移瘤患者生存的个体化列线图
Front Oncol. 2021 May 13;11:659538. doi: 10.3389/fonc.2021.659538. eCollection 2021.
4
Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors.肺癌中弥漫性肺内转移的影像学特征与表皮生长因子受体抑制剂的预后不良相关。
Cancer Manag Res. 2020 Nov 17;12:11761-11772. doi: 10.2147/CMAR.S261983. eCollection 2020.
5
The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases.表皮生长因子受体(EGFR)突变状态及单发脑转移对非小细胞肺癌脑转移患者生存的影响
Neurooncol Adv. 2020 May 28;2(1):vdaa064. doi: 10.1093/noajnl/vdaa064. eCollection 2020 Jan-Dec.
6
Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.表皮生长因子受体突变和间变性淋巴瘤激酶重排对非小细胞肺癌脑转移患者结局的影响。
Neuro Oncol. 2020 Feb 20;22(2):267-277. doi: 10.1093/neuonc/noz155.
7
MicroRNA-330-3p promotes brain metastasis and epithelial-mesenchymal transition via GRIA3 in non-small cell lung cancer.微小RNA-330-3p通过GRIA3促进非小细胞肺癌的脑转移和上皮-间质转化。
Aging (Albany NY). 2019 Sep 8;11(17):6734-6761. doi: 10.18632/aging.102201.
阿法替尼对比顺铂加吉西他滨用于治疗亚洲表皮生长因子受体突变阳性的晚期非小细胞肺癌患者的一线治疗(LUX-Lung 6):一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15.
4
Cancer statistics, 2014.癌症统计数据,2014 年。
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
5
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.肺癌中酪氨酸激酶抑制剂耐药性发展的新兴模式。
J Clin Oncol. 2013 Nov 1;31(31):3987-96. doi: 10.1200/JCO.2012.45.2029. Epub 2013 Oct 7.
6
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.III 期研究阿法替尼或顺铂加培美曲塞治疗 EGFR 突变的转移性肺腺癌患者。
J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
7
Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer.III 期和 IV 期非小细胞肺癌患者的转诊和治疗模式。
J Oncol Pract. 2013 Jan;9(1):42-50. doi: 10.1200/JOP.2012.000640.
8
Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma.表皮生长因子受体酪氨酸激酶抑制剂耐药与表皮生长因子受体突变型肺腺癌脑转移放疗疗效的关系。
Anticancer Res. 2013 Apr;33(4):1649-55.
9
Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network.癌症研究网络中晚期非小细胞肺癌成人患者一线化疗的应用模式和预测因素。
Lung Cancer. 2012 Dec;78(3):245-52. doi: 10.1016/j.lungcan.2012.09.008. Epub 2012 Sep 27.
10
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma.肺腺癌患者脑脊液中吉非替尼浓度。
Clin Lung Cancer. 2013 Mar;14(2):188-93. doi: 10.1016/j.cllc.2012.06.004. Epub 2012 Jul 28.